clinical trial · NCT06650761
A Phase I Study of CDX-622
Healthy ParticipantsCDX-622Normal Saline
brief summary
This is a study to determine the safety of CDX-622 in healthy participants.
started
Nov 1, 2024
primary completion
Apr 24, 2026
completion
Apr 24, 2026
last updated
May 4, 2026
detailed description
CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP).
This study will evaluate the safety, pharmacokinetics, and Pharmacodynamics of IV single ascending doses (Part 1), IV multiple ascending doses (Part 2), and subcutaneous (SC) single ascending doses (Part 3) of CDX-622 in healthy participants.
official title
A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol